ArticleRMD open2019

Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs? A Danish register-based study of patients with inflammatory arthritis.

Bente Glintborg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.